Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia.
about
Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumoniaHumanized Mouse Models of Staphylococcus aureus Infection.Characteristics of invasive Staphylococcus aureus infections in three regions of Korea, 2009-2011: a multi-center cohort studyNosocomial methicillin resistant Staphylococcus aureus pneumonia - epidemiology and trends based on data of a network of 586 German ICUs (2005-2009)Decolonization of methicillin-resistant Staphylococcus aureus during routine hospital care: Efficacy and long-term follow-up.Differences in hospital- and ventilator-associated pneumonia due to Staphylococcus aureus (methicillin-susceptible and methicillin-resistant) between Europe and Latin America: a comparison of the EUVAP and LATINVAP study cohorts.Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infectionAntimicrobial activity of wild mushroom extracts against clinical isolates resistant to different antibiotics.Factors associated with variation in estimates of the cost of resistant infectionsCharacterization of Staphylococcus aureus isolates with a partial or complete absence of staphylococcal cassette chromosome elements.Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials.Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitalsCost-effectiveness of strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in an intensive care unitBacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study.Healthcare utilization and costs associated with S. aureus and P. aeruginosa pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database.Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus.Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia modelAttributable cost of methicillin resistance: an issue that is difficult to evaluate.Epidemiology of staphylococcal resistance.Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005Bench-to-bedside review: Association of genetic variation with sepsisCandidemia on presentation to the hospital: development and validation of a risk score.Year in review 2009: Critical Care--shock.Overview of antimicrobial therapy in intensive care units.Economic features of antibiotic resistance: the case of methicillin-resistant Staphylococcus aureus.Risk factors for ventilator-associated pneumonia among patients undergoing major oncological surgery for head and neck cancer.Progression and variability of physiologic deterioration in an ovine model of lung infection sepsis.Rapid diagnostic test and use of antibiotic against methicillin-resistant Staphylococcus aureus in adult intensive care unit.The impact of healthcare-associated methicillin-resistant Staphylococcus aureus infections on post-discharge healthcare costs and utilization.Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection.Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection?Safety of Staphylococcus aureus four-antigen and three-antigen vaccines in healthy adults: A meta-analysis of randomized controlled trials.Inducible Costimulator Contributes to Methicillin-Resistant Staphylococcus aureus Pneumonia.In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus.Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation.Effizientes MRSA-Management
P2860
Q24650729-2A36A4F2-6F6E-4B13-A4B8-E049A31FA269Q33634034-3241DC1D-8E38-47C2-AFA8-22514A7B0281Q33644439-875362BA-D639-49C3-8BAD-FB4833A000F0Q33773159-26CA09D0-5216-44E2-88A0-7A2496FC35CEQ33779980-7B9D4110-EFD2-498E-8DB6-C4310D69754CQ33790761-30026394-431E-4233-82BF-4F9751923F7AQ33797936-D1713AB5-F796-46F9-91C2-5F9CDF250879Q34032035-E2778697-5903-4D2D-B633-4B00BBD9CC9FQ34077002-9895252E-4AD5-4467-89EA-DFB7C6CF05A0Q34190522-19009450-1882-4238-9C54-2331A00450C1Q34446914-CC30E8E8-BC6C-4934-B008-EB745C4981ABQ34478074-55961C8F-B1A1-4859-8D94-D46E65B25BB9Q34923394-EA007DDD-2B44-48A4-93C3-7BC07A1861AFQ34999500-C9D6B009-CA4B-4AEA-B7F1-B8424A7F48C6Q35029581-67AC7E8C-2C18-4584-91B5-71869140CE16Q35567016-EA78F28B-3A8C-4B79-BD81-F6497CB3C631Q35669486-299529E3-6A57-4F7A-B73D-9D73A1B0FC76Q35942872-8780C8DD-03E7-47CE-9A6F-826A9CE8C1A1Q36364009-62C2CC66-058A-4967-901B-1235B7D8BF13Q36577961-5782E12A-71CF-45D9-9043-8944E1E00448Q36916068-BCADE785-C8AF-43FB-AF8A-CFE3E0D5F295Q37072281-22783D0B-167A-41A1-8994-06719166CF03Q37210026-B9D28767-4C63-4CA7-BB4C-FD7E51B87007Q37443115-E6B71D3A-8315-45CC-8494-6A756B6FA29CQ37814495-5EF0A263-4944-440F-AFA8-2FE1D762F435Q37822457-EF596A5C-B521-4B62-8D30-6093C84BC50BQ38275128-3637165D-8CF4-4C29-AFFF-70D3CDCC5E38Q40217473-2B97ED19-98CD-4DC1-8279-866AE6B01B71Q40225799-B5F17B53-566A-4BB1-8733-96A5BB4F8A42Q40514279-FB1B65AD-9F56-4790-9B29-C049F8E106BAQ41348984-4573B7CE-9AD4-4F2B-A0E1-81137DB21F80Q43149693-9711EA76-F9B1-4EC2-A232-709F603A6C7DQ46062559-C37AE082-885F-4452-84B6-8C721DD4DD69Q47730135-1E9B40B3-B7AB-45CC-AB20-A4CBE21667A6Q49604318-5C5B8A8C-D97D-4E30-BA63-10E80B693152Q50723093-081B3DFE-2C5E-46F5-BB6D-74A9C51C2474Q54957598-8A596111-3337-4A0B-B147-57312D72C70AQ58570777-6DA3BA3D-782C-464B-BC31-56BEB76BFBC4
P2860
Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Morbidity and cost burden of m ...... ntilator-associated pneumonia.
@ast
Morbidity and cost burden of m ...... ntilator-associated pneumonia.
@en
Morbidity and cost burden of m ...... ntilator-associated pneumonia.
@nl
type
label
Morbidity and cost burden of m ...... ntilator-associated pneumonia.
@ast
Morbidity and cost burden of m ...... ntilator-associated pneumonia.
@en
Morbidity and cost burden of m ...... ntilator-associated pneumonia.
@nl
prefLabel
Morbidity and cost burden of m ...... ntilator-associated pneumonia.
@ast
Morbidity and cost burden of m ...... ntilator-associated pneumonia.
@en
Morbidity and cost burden of m ...... ntilator-associated pneumonia.
@nl
P2093
P2860
P921
P356
P1433
P1476
Morbidity and cost burden of m ...... ntilator-associated pneumonia.
@en
P2093
Andrew F Shorr
Larry Z Liu
R S Johannes
Vikas Gupta
Ying P Tabak
P2860
P2888
P356
10.1186/CC4934
P577
2006-06-29T00:00:00Z